ResMed Earnings on Deck: What to Expect From RMD

ResMed Inc. (NYSE: RMD), a global leader in sleep and respiratory care devices, is set to release its first quarter fiscal year 2026 earnings before the market opens tomorrow. The report will be closely scrutinized by investors seeking to gauge the company's performance amidst evolving market dynamics and increasing competitive pressures.

As of today, ResMed shares are trading at $255.64, down 0.36% from the previous close. This dip comes ahead of the earnings release, reflecting potential investor caution, with RMD trading at a level of significant support.

Technical indicators show the stock price is currently below its 50-day simple moving average (SMA) of $275.38, but above its 200-day SMA of $251.26. This positioning suggests a period of uncertainty, with the short-term trend indicating downward momentum, while the longer-term trend remains positive.

Following the earnings release, ResMed's management will host a live webcast to discuss the results and provide forward-looking guidance. The webcast is scheduled for 1:30 p.m. PDT / 4:30 p.m. EDT and can be accessed via the ResMed Investor Relations website. A replay will be available shortly after the live event.

Analysts are projecting earnings of $2.49 per share and revenue of $1.3332 billion for the quarter.

Price Targets

Despite the recent challenges, analysts remain cautiously optimistic about ResMed's prospects. The average price target for the stock is $301.09, implying a potential upside of approximately 11.43% from the current trading price. This target suggests that analysts believe ResMed has the potential to overcome its current headwinds and deliver future growth.